Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis

被引:546
作者
Fearon, KC
Voss, AC
Hustead, DS
机构
[1] Univ Edinburgh, Dept Clin & Surg Sci Surg, Royal Infirm, Edinburgh EH16 4SA, Midlothian, Scotland
[2] Abbott Labs, Ross Prod Div, Columbus, OH USA
关键词
systemic inflammation; food intake; cachexia; prognosis;
D O I
10.1093/ajcn/83.6.1345
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 [营养与食品卫生学];
摘要
Background: Cancer cachexia is a multifactorial syndrome that is poorly defined. Objective: Our objective was to evaluate whether a 3-factor profile incorporating weight loss (>= 10%), low food intake (<= 1500 kcal/d), and systemic inflammation (C-reactive protein >= 10 mg/L) might relate better to the adverse functional aspects of cachexia and to a patient's overall prognosis than will weight loss alone. Design: One hundred seventy weight-losing (>= 5%) patients with advanced pancreatic cancer were screened for nutritional status, functional status, performance score, health status, and quality of life. Patients were followed for a minimum of 6 mo, and survival was noted. Patients were characterized by using the individual factors, !,2 factors, or all 3 factors. Results: Weight loss alone did not define a population that differed in functional aspects of self-reported quality of life or health status and differed only in objective factors of physical function. The 3-factor profile identified both reduced subjective and objective function. In the overall population, the 3 factors, >= 2 factors, and individual profile factors (except weight loss) all carried adverse prognostic significance (P < 0.01). Subgroup analysis showed that the 3-factor profile carried adverse prognostic significance in localized (hazard ratio: 4.9; P < 0.001) but not in metastatic disease. Conclusions: Weight loss alone does not identify the full effect of cachexia on physical function and is not a prognostic variable. The 3-factor profile (weight loss, reduced food intake, and systemic inflammation) identifies patients with both adverse function and prognosis. Shortened survival applies particularly to cachectic patients with localized disease, thereby reinforcing the need for early intervention.
引用
收藏
页码:1345 / 1350
页数:6
相关论文
共 23 条
[1]
THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]
[Anonymous], 1990, Q REV BIOL
[3]
Cancer cachexia:: the molecular mechanisms [J].
Argilés, JM ;
Moore-Carrasco, R ;
Fuster, G ;
Busquets, S ;
López-Soriano, FJ .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (04) :405-409
[4]
Bingham S, 1982, Nutr Cancer, V4, P23, DOI 10.1080/01635588209513735
[5]
Blackburn G L, 1977, JPEN J Parenter Enteral Nutr, V1, P11, DOI 10.1177/014860717700100111
[6]
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[7]
Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms [J].
Cleeland, CS ;
Bennett, GJ ;
Dantzer, R ;
Dougherty, PM ;
Dunn, AJ ;
Meyers, CA ;
Miller, AH ;
Payne, R ;
Reuben, JM ;
Wang, XS ;
Lee, BN .
CANCER, 2003, 97 (11) :2919-2925
[8]
PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS [J].
DEWYS, WD ;
BEGG, C ;
LAVIN, PT ;
BAND, PR ;
BENNETT, JM ;
BERTINO, JR ;
COHEN, MH ;
DOUGLASS, HO ;
ENGSTROM, PF ;
EZDINLI, EZ ;
HORTON, J ;
JOHNSON, GJ ;
MOERTEL, CG ;
OKEN, MM ;
PERLIA, C ;
ROSENBAUM, C ;
SILVERSTEIN, MN ;
SKEEL, RT .
AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) :491-497
[9]
FALCONER JS, 1995, CANCER, V75, P2077, DOI 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO
[10]
2-9